Madrigal Pharmaceuticals, Inc. MDGL Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s accounts receivable?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported accounts receivable of $187.36M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s accounts receivable changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s accounts receivable increased by 205.0% year-over-year, from $61.43M to $187.36M.
- What does accounts receivable mean?
- The amount of money customers owe the company for products or services already provided.
- How do you interpret accounts receivable?
- An increase relative to revenue may signal collection issues, while a decrease indicates efficient cash conversion cycles.
- How does accounts receivable compare across companies?
- Varies significantly based on the commercial stage of the company and its specific payment terms.